The list honors the “top law professionals in Los Angeles” for their “ongoing efforts as outstanding legal stewards.” Ms. Chou’s profile is here.
Month: April 2026
Zaccaro, Vo and Tan Publish Article on SEC Disgorgement Remedy
The article looks at legal arguments relating to the SEC’s disgorgement remedy and the U.S. Supreme Court’s seeming reluctance to limit it. The article is here.
Hueston Hennigan Secures Significant Victory for Samsung Bioepis at Third Circuit
Samsung Bioepis is a biopharmaceutical company focused on increasing patient access to high-quality medicines by developing and manufacturing biosimilars. Janssen’s preliminary injunction motion sought to prevent Samsung Bioepis from launching its ustekinumab biosimilar with partner Quallent Pharmaceuticals. The preliminary injunction motion threatened Samsung’s ability to commercialize its biosimilar drug, which treats inflammatory conditions including moderate-to-severe plaque psoriasis and psoriatic arthritis, and put several important commercial relationships for the company at risk.
In April 2025, the Hueston Hennigan team defeated Janssen’s motion at the district court, with the court holding that Janssen had failed to show irreparable harm in the absence of a preliminary injunction. Janssen subsequently appealed to the Third Circuit. While the appeal was pending, in January 2026, the team defeated a second motion for a preliminary injunction brought by Janssen in the district court.
In a unanimous precedential opinion issued on April 14, 2026, the Third Circuit affirmed the district court’s denial of Janssen’s first motion for a preliminary injunction. The court agreed with Samsung Bioepis’s articulation of the standard for showing irreparable harm, and held that Janssen had failed to show that it would suffer such harm.
“We agree with the court’s well-reasoned decision,” said attorney for Samsung Bioepis, Hagan Scotten. “The ruling represents an important win for Samsung Bioepis and its ability to offer its biosimilar drug in the United States.”
In addition to Scotten, the Hueston Hennigan team includes John Hueston, Christine Woodin, Karen Ding, Bram Alden, Chandler Matz and Katie Ross.
The case is Johnson & Johnson et al. v. Samsung Bioepis Co. Ltd., No. 25-1831 (3rd Cir.) and 25-cv-01439 (D.N.J.).
Hueston, Jackson and Kaba Named DJ ‘Leading Commercial Litigators’
This highly competitive list honors 100 California attorneys who have “built careers on bet-the-company cases – with outcomes that matter for their clients, their industries and the law itself.” Hueston Hennigan had the most honorees of any firm on the list.
Their profiles are here, here and here (subscription required).